Last reviewed · How we verify
NCT05319119
Fractional Flow Reserve Derived From CT Related Treatment
trial in Coronary Angiography in 1,000 participants. Status unknown.
6 April 2022
Quick facts
| Lead sponsor | Henan Institute of Cardiovascular Epidemiology |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 29 March 2022 |
| Primary completion | 6 April 2022 |
| Estimated completion | 29 April 2022 |
| Sites | 1 location across China |
Conditions studied
- Coronary Angiography — all drugs for Coronary Angiography →
- Fractional Flow Reserve, Myocardial — all drugs for Fractional Flow Reserve, Myocardial →
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
Sponsor
Henan Institute of Cardiovascular Epidemiology
Who can join
Adults 18 to 75, any sex, with Coronary Angiography or Fractional Flow Reserve, Myocardial. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a retrospective, single-center study.This experiment aims to explore the influence of CT-FFR as a relevant for revascularization on the prognosis of patients with coronary heart disease, assessing concurrent on different basis the difference of prognosis of patients with revascularization was analyzed, and the significance of revascularization related by CT-FFR was analyzed.This study is a retrospective study. The treatment strategies of all patients are based on the results of CAG，including coronary revascularization.After calculating the CT-FFR value, the above doctors will formulate treatment strategies based on the results and formulate treatment strategies retrospectively.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05319119
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Angiography
Currently open trials in the same condition.
- NCT04982419 — Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial · Phase 2, PHASE3 · recruiting
Other Henan Institute of Cardiovascular Epidemiology trials
Trials by the same sponsor.
- NCT07514624 — CRIC Combined With MFT for MFR in Patients With Incomplete Revascularization of CAD · NA · not yet recruiting
- NCT06820970 — CRIC Combined With MFT for Cardiovascular Adverse Events in Patients With Incomplete Revascularization of CAD · NA · recruiting
- NCT06769256 — Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden · Phase 4 · recruiting
- NCT07181356 — Effects of Long-term Remote Ischemic Preconditioning on Clinical Outcome in Patients With Acute Myocardial Infarction · NA · recruiting
- NCT04308551 — Effect of Indobufen and Aspirin on Platelet Aggregation and Long Term Prognosis in Patients With Coronary Heart Disease · NA · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05319119 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Henan Institute of Cardiovascular Epidemiology
- Last refreshed: 8 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05319119.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing